177 related articles for article (PubMed ID: 26663557)
1. Genotyping HLA-B*5801 for Allopurinol-Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method.
Cheng L; Zhang L; Gao L; Zhang W; Chen X; Zhou HH
Clin Transl Sci; 2015 Dec; 8(6):834-6. PubMed ID: 26663557
[TBL] [Abstract][Full Text] [Related]
2. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
3. Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR.
Zhang X; Ma H; Hu C; Yu B; Ma W; Wu Z; Luo X; Zou H; Guan M
Clin Chem Lab Med; 2015 Feb; 53(3):383-90. PubMed ID: 25257159
[TBL] [Abstract][Full Text] [Related]
4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
5. Rapid, Reliable, and Inexpensive
Huh JY; Han OJ; Park G
Ann Clin Lab Sci; 2018 May; 48(3):296-300. PubMed ID: 29970431
[TBL] [Abstract][Full Text] [Related]
6. Comparison between the
Saksit N; Nakkam N; Konyoung P; Khunarkornsiri U; Tassaneeyakul W; Chumworathayi P; Kanjanawart S; Sukasem C; Sangviroon A; Pattanacheewapull O; Tassaneeyakul W
J Immunol Res; 2017; 2017():2738784. PubMed ID: 29392141
[TBL] [Abstract][Full Text] [Related]
7. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the HLA-B
Park HW; Kim DK; Kim SH; Kim S; Chae DW; Yang MS; Oh YK; Lee JP; Jung JW; Shin J; Hwang JH; Kang MG; Kim SM; Kwon SK; Kim HY; Kim MH; Kim SJ; Ryu DR; Cho YJ; Jee YK; Kim SM; Lee EK; Kim JY; Cho HS; Jeong YY; Kim SH; Jun JB; Park JS; Kim GH; Kim S; Jung HY; Lee JM
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1271-1276. PubMed ID: 30580048
[TBL] [Abstract][Full Text] [Related]
9. HLA-B*58: 01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol.
Peng K; Bjork J; Wen YF; Roman YM; Culhane-Pera K; Lo MX; Gertner E; Straka RJ
Pharmacogenet Genomics; 2020 Feb; 30(2):21-25. PubMed ID: 31658186
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of allopurinol--making an old drug safer.
Lam MP; Yeung CK; Cheung BM
J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
[TBL] [Abstract][Full Text] [Related]
12. The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers.
Shim JS; Yun J; Kim MY; Chung SJ; Oh JH; Kang DY; Jung JW; Cho SH; Kang HR
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1261-1270. PubMed ID: 30529060
[TBL] [Abstract][Full Text] [Related]
13. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
14. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.
Cao ZH; Wei ZY; Zhu QY; Zhang JY; Yang L; Qin SY; Shao LY; Zhang YT; Xuan JK; Li QL; Xu JH; Xu F; Ma L; Huang HY; Xing QH; Luo XQ
Pharmacogenomics; 2012 Jul; 13(10):1193-201. PubMed ID: 22909208
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs.
Klaewsongkram J; Sukasem C; Thantiworasit P; Suthumchai N; Rerknimitr P; Tuchinda P; Chularojanamontri L; Srinoulprasert Y; Rerkpattanapipat T; Chanprapaph K; Disphanurat W; Chakkavittumrong P; Tovanabutra N; Srisuttiyakorn C;
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):219-227.e4. PubMed ID: 29800753
[TBL] [Abstract][Full Text] [Related]
16. Utility of human leukocyte antigen-B*58: 01 genotyping and patient outcomes.
Ke CH; Chung WH; Tain YL; Huang YB; Wen YH; Chuang HY; Hsu CN
Pharmacogenet Genomics; 2019 Jan; 29(1):1-8. PubMed ID: 30379713
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
[TBL] [Abstract][Full Text] [Related]
18. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
Tan-Koi WC; Sung C; Chong YY; Lateef A; Pang SM; Vasudevan A; Aw D; Lui NL; Lee SX; Ren EC; Koay ES; Tay YK; Lim YL; Lee HY; Dong D; Loke C; Tan L; Limenta M; Lee EJ; Toh D; Chan CL
Pharmacogenomics; 2017 Jun; 18(9):881-890. PubMed ID: 28594314
[TBL] [Abstract][Full Text] [Related]
19. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
20. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.
Chiu ML; Hu M; Ng MH; Yeung CK; Chan JC; Chang MM; Cheng SH; Li L; Tomlinson B
Br J Dermatol; 2012 Jul; 167(1):44-9. PubMed ID: 22348415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
